^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    vandortuzumab vedotin (RG7450)

    i
    Other names: RG7450, DSTP3086S, anti-steap1 adc, MSTP2109A
    Company:
    Roche
    Drug class:
    Microtubule inhibitor, STEAP1-targeted antibody-drug conjugate
    Related drugs:
    3years
    Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer (clinicaltrials.gov)
    P1/2, N=27, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2021 --> Jan 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    STEAP1 (STEAP Family Member 1)
    |
    vandortuzumab vedotin (RG7450)
    almost4years
    Pharmacokinetics and Biodistribution of [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. (PubMed, Mol Pharm)
    The pharmacokinetics were similar to other antibodies without major cross-reactivity with normal tissues. A more detailed analysis of lesion targeting in a larger patient population with correlation to immunohistology and standard imaging modalities has been reported.
    Clinical • PK/PD data • Journal
    |
    STEAP1 (STEAP Family Member 1)
    |
    vandortuzumab vedotin (RG7450)
    4years
    Imaging metastatic castration-resistant prostate cancer patients with Zr-DFO-MSTP2109A anti-STEAP1 antibody. (PubMed, J Nucl Med)
    Zr-DFO-MSTP2109A is well tolerated and shows localization in mCRPC sites in bone and soft tissue. Given the high SUV in tumor and localization of a large number of lesions, this reagent warrants further exploration as a companion diagnostic in patients undergoing STEAP1-directed therapy.
    Clinical • Journal
    |
    KLK3 (Kallikrein-related peptidase 3)
    |
    vandortuzumab vedotin (RG7450)
    4years
    Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer (clinicaltrials.gov)
    P1/2, N=27, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2020 --> Jan 2021 | Trial primary completion date: Jan 2020 --> Jan 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    STEAP1 (STEAP Family Member 1)
    |
    vandortuzumab vedotin (RG7450)
    5years
    Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer (clinicaltrials.gov)
    P1/2, N=27, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2019 --> Jan 2020
    Clinical • Trial completion date • Trial primary completion date
    |
    STEAP1 (STEAP Family Member 1)
    |
    vandortuzumab vedotin (RG7450)